Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
- Conditions
- HIV Infections
- Interventions
- Biological: ALVAC-HIV (vCP2438)Biological: PlaceboBiological: Bivalent Subtype C gp120/MF59
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 5404
- Registration Number
- NCT02968849
- Locations
- 🇿🇦
Emavundleni CRS, Cape Town, Western Cape, South Africa
🇿🇦Khayelitsha CRS, Cape Town, Western Cape, South Africa
🇿🇦Kliptown Soweto CRS, Johannesburg, Gauteng, South Africa
A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
- Conditions
- Zika Virus Infection
- Interventions
- Other: PlaceboBiological: IXIAROBiological: Zika Virus Purified Inactivated Vaccine (ZPIV)Biological: YF Vax 17D Strain
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2024-04-22
- Target Recruit Count
- 75
- Registration Number
- NCT02963909
- Locations
- 🇺🇸
Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2020-08-25
- Target Recruit Count
- 211
- Registration Number
- NCT02961751
- Locations
- 🇺🇸
Los Angeles Lesbian Gay Bisexual/Transgender Center, Los Angeles, California, United States
🇺🇸University of California, San Diego Health - Owen Clinic, San Diego, California, United States
🇺🇸AIDS Healthcare Foundation Wellness Center - Hollywood, Los Angeles, California, United States
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
- Conditions
- Influenza A Virus, H7N9 Subtype
- Interventions
- Biological: H7N9 pIIVBiological: H7N9 pLAIVBiological: AS03 adjuvant
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2018-10-02
- Target Recruit Count
- 53
- Registration Number
- NCT02957656
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
ZIKA Vaccine in Naive Subjects
- Conditions
- Zika Virus Infection
- Interventions
- Drug: SalineBiological: Zika Virus Purified Inactivated Vaccine (ZPIV)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2018-12-07
- Target Recruit Count
- 91
- Registration Number
- NCT02952833
- Locations
- 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PlaceboBiological: RSV LID ΔM2-2 1030s vaccine
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2018-02-13
- Target Recruit Count
- 33
- Registration Number
- NCT02952339
- Locations
- 🇺🇸
Center for Immunization Research, Baltimore, Maryland, United States
🇺🇸Center for Immunization Research South, Laurel, Maryland, United States
Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
- Conditions
- Influenza, Human
- Interventions
- Biological: Seasonal LAIVBiological: PlaceboBiological: Wild-type A/California/2009-like Influenza Virus
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PlaceboBiological: RSV LID cp ΔM2-2 Vaccine
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2018-08-17
- Target Recruit Count
- 8
- Registration Number
- NCT02948127
- Locations
- 🇺🇸
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸Center for Immunization Research East, Johns Hopkins Bayview Medical Center Campus, Baltimore, Maryland, United States
🇺🇸Center for Immunization Research South, Laurel, Maryland, United States
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
- Conditions
- Malaria
- Interventions
- Biological: Pfs25M-EPABiological: Pfs230D1M-EPABiological: Engerix-BOther: AS01Biological: MenactraOther: Normal SalineDrug: Coartem
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 301
- Registration Number
- NCT02942277
- Locations
- 🇲🇱
Bancoumana Malaria Vaccine Center, Bamako, Mali
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
- Conditions
- InfluenzaAvian InfluenzaH1N1 Influenza
- Interventions
- Drug: AS03Biological: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203Biological: Monovalent influenza A/H7N9 virus vaccine
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 30
- Registration Number
- NCT02921997
- Locations
- 🇺🇸
Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville, Tennessee, United States